Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Copegus Meets Generic Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves ANDAs filed by Three Rivers, Teva and Zydus, with Three Rivers offering a higher-dose tablet than currently available from the brand company.

You may also be interested in...



Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity

Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.

CellTrans’ Donislecel Gets US FDA Panel Nod For Small Group Of Type 1 Diabetics

Benefits of independence from exogenous insulin outweighed the risks from long-term immunosuppression necessary with the allogeneic pancreatic islet cellular therapy, majority of panelists said, but they urged the FDA to limit the indication to a very small subpopulation of patients.

US FDA Oncology Center Wants Trial Datasets Flagged As Remote Or In-Person Assessments

Agency wants to use pandemic-interrupted clinical trials to gauge how decentralized approaches impacted study integrity and to inform prospective use of such designs post-COVID.

Topics

UsernamePublicRestriction

Register

PS061483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel